Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2016

01-11-2016 | Editorial Commentary

How reliable is 18FDG PET for predicting the onset of Huntington’s disease?

Author: Andrea Ciarmiello

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2016

Login to get access

Excerpt

In the current issue of the European Journal of Nuclear Medicine and Molecular Imaging, López-Mora et al. present a study evaluating the cortical and striatal 18F-FDG PET/CT uptake in a cohort of Huntington’s disease (HD) mutation carriers in preclinical and manifest stages of the disease. The authors found a progressive metabolic striatal decrease in subjects with preclinical HD as compared with controls and subjects with manifest HD, indicating the value of 18F-FDG PET/CT as a possible predictor of the onset of HD. The findings are consistent with those of previous studies highlighting early striatal involvement in gene mutation carriers without motor symptoms and, therefore, still clinically considered far from onset. …
Literature
1.
The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–83.CrossRef
2.
Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994;330(20):1401–6.CrossRefPubMed
3.
Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537–48.CrossRefPubMed
4.
Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR; International Huntington’s Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004;65(4):267–77.CrossRefPubMed
5.
Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci U S A. 2004;101(10):3498–503.CrossRefPubMedPubMedCentral
6.
Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet. 1993;4(4):398–403.CrossRefPubMed
7.
Telenius H, Kremer HP, Theilmann J, Andrew SE, Almqvist E, Anvret M, et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet. 1993;2(10):1535–40.CrossRefPubMed
8.
Ranen NG, Stine OC, Abbott MH, Sherr M, Codori AM, Franz ML, et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet. 1995;57(3):593–602.PubMedPubMedCentral
9.
Kuhl DE. Imaging local brain function with emission computed tomography. Radiology. 1984;150(3):625–31.CrossRefPubMed
10.
Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986;20(3):296–303.CrossRefPubMed
11.
Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. N Engl J Med. 1987;316(7):357–62.CrossRefPubMed
12.
Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, et al. Positron emission tomographic scan investigations of Huntington’s disease: cerebral metabolic correlates of cognitive function. Ann Neurol. 1988;23(6):541–6.CrossRefPubMed
13.
Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington’s disease. Neurology. 1986;36(7):888–94.CrossRefPubMed
14.
Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47(2):215–22.PubMed
15.
Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA. Correlation between the onset age of Huntington’s disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet. 1993;2(10):1547–9.CrossRefPubMed
16.
Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39(6):1030–6.CrossRefPubMed
17.
van Duijn E, Kingma EM, Timman R, Zitman FG, Tibben A, Roos RA, et al. Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington’s disease compared with mutation-negative first-degree relatives. J Clin Psychiatry. 2008;69(11):1804–10.CrossRefPubMed
18.
Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain. 2007;130(Pt 11):2858–67.CrossRefPubMedPubMedCentral
19.
Ginsberg MD, Lockwood AH, Busto R, Finn RD, Butler CM, Cendan IE, et al. A simplified in vivo autoradiographic strategy for the determination of regional cerebral blood flow by positron emission tomography: theoretical considerations and validation studies in the rat. J Cereb Blood Flow Metab. 1982;2(1):89–98.CrossRefPubMed
20.
Howard BE, Ginsberg MD, Hassel WR, Lockwood AH, Freed P. On the uniqueness of cerebral blood flow measured by the in vivo autoradiographic strategy and positron emission tomography. J Cereb Blood Flow Metab. 1983;3(4):432–41.CrossRefPubMed
21.
Ciarmiello A, Giovannini E, Meniconi M, Cuccurullo V, Gaeta MC. Hybrid SPECT/CT imaging in neurology. Curr Radiopharm. 2014;7(1):5–11.CrossRefPubMed
Metadata
Title
How reliable is 18FDG PET for predicting the onset of Huntington’s disease?
Author
Andrea Ciarmiello
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3483-5

Other articles of this Issue 12/2016

European Journal of Nuclear Medicine and Molecular Imaging 12/2016 Go to the issue

Original Article

Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer

Original Article

Striatal hypometabolism in premanifest and manifest Huntington’s disease patients

Letter to the Editor

Comments on Van den Wyngaert et al., The EANM practice guidelines for bone scintigraphy

Original Article

Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351

Original Article

Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer

Letter to the Editor

Strategy based on kinetics of O-(2-[18F] fluoroethyl)-L-tyrosine ([18F] FET)